secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001104659-23-088821
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports Q2 2023 net loss $106.5M, cash $317.3M; lifileucel PDUFA Nov 25
-------------------------------------------------------------------------------

- FDA set PDUFA date Nov 25, 2023 for lifileucel BLA in advanced melanoma under priority review.
- Cash $317.3M at June 30; raised ~$161.4M from July public offering; expects funding into end of 2024.
- Q2 2023 net loss $106.5M ($0.47/sh) vs $99.3M ($0.63/sh) in Q2 2022; R&D expense up to $86.3M.
- Revenue $0.2M from Proleukin acquisition in May 2023; no revenue in prior-year period.
- Registrational NSCLC trial IOV-LUN-202: 26.1% ORR in preliminary analysis; enrollment continuing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/0001104659-23-088821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923088821/tm2323093d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer